IIQ ASX Chart
Snapshot
INOVIQ Ltd (IIQ) is a biotechnology company pioneering next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialized its fast, efficient and specific EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumors.
Share Price Activity (ASX)
Last (Price) | |
Change | 0.00 (0.00) |
Bid / Ask | - |
Volume | |
Volume (4w avg) | |
Turnover | |
Open | |
Day Range | - |
VWAP | |
Prev Close | |
Last Trade |
Performance
1 Week | |
1 Month | |
2025 YTD | |
1 Year | |
vs Sector (1yr) | - |
vs ASX 200 (1yr) | -47.30% |
Announcements
Corporate Overview
Corporate Details
Head Office | Notting Hill VIC 3168 |
Website | www.inoviq.com |
Registry | Computershare |
Auditor | Grant Thornton Audit Pty Ltd |
Date Listed | - |
Upcoming Calendar (Forecasted)
Date | Event |
---|---|
20/08/2025 | Report (Prelim) |
19/09/2025 | Report (Annual) |
20/02/2026 | Report (Interim) |
Former Company Names
- BARD1 Life Sciences Limited (BD1 ), 08/12/2021.
- Eurogold Limited (EUG), (10/06/2016)
- Esmeralda Exploration Limited (EUG), 16/05/2002
Sponsored Financial Content
Dividend History
DPS and Yield calculations use the Pay Date.
See Upcoming Dividends for all ASX companies.
Directors & Management
Directors
Management
Director Transactions
IIQ directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
Director Interests
The current holdings of IIQ directors.
Shareholder Info
Substantial Shareholders
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
Note: If a substantial shareholder's stake drops below 5%, the "Shareholders Selling" field shows full ownership as sold and sets "New %" to zero, even if they continue to hold shares under the limit.
Name | Last Notice | Total Shares | Shares Held (%) |
---|---|---|---|
Merchant Funds Manageement Pty Ltd | 02/09/2024 | 13,082,057 | 14.22 |
Merchant Funds Management Pty Ltd | 13/09/2024 | 11,666,332 | 10.46 |
Shareholders Buying
12 month transaction history compiled from ASX announcements.
Date | Name | Bought | Previous % | New % |
---|---|---|---|---|
13-09-24 | Biotech Capital Management Pty Ltd | 7,176,284 | -- | 6.43 |
Shareholders Selling
12 month transaction history compiled from ASX announcements.
Date | Name | Sold | Previous % | New % |
---|---|---|---|---|
17-03-25 | Biotech Capital Management Pty Ltd | 7,176,284 | 6.43 | -- |
13-09-24 | Merchant Funds Management Pty Ltd | 1,415,725 | 14.22 | 10.46 |
Historical Data
Share Price History
Date | Close | Change | %Chg | Open | High | Low | Volume | Turnover |
---|---|---|---|---|---|---|---|---|
Historical Data
Year | Closing Price | Last Trade |
---|---|---|
2024 | $0.56 | 28 June |
2023 | $0.85 | 30 June |
2022 | $0.39 | 30 June |
2021 | $1.88 | 30 June |
2020 | $0.027 | 30 June |
2019 | $0.029 | 28 June |
2018 | $0.014 | 29 June |
2017 | $0.01 | 30 June |
2016 | $0.022 | 30 June |
2015 | $0.03 | 30 June |
2014 | $0.03 | 30 June |
Important note:
All year-end and CSV data is "as traded on the day" and ignores corporate actions (e.g. share splits)

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.